Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN & Breslow JL (1992) Mechanism of hypertriglyceridemia in human apolipoprotein (Apo) CIII transgenic mice. Diminished very low density lipoprotein fraction catabolic rate associated with increased Apo CIII and reduced Apo E on the particles. J Clin Invest 90, 1889–1900.
American Institute of Nutrition (1977) Report of the American Institute of Nutrition ad hoc writing committee on standard diets for nutritional studies. J Nutr 107, 1340–1348.
Berthou L, Duverger N & Emmanuel F, et al. (1996) Opposite regulation of human versus mouse apolipoprotein A-1 by fibrates in human apolipoprotein A-1 transgenic mice. J Clin Invest 97, 2408–2416.
Brenner H, Rothenbacher D, Bode G, März W, Hoffmeister A & Koenig W (2001) Coronary heart disease risk reduction in a predominantly beer-drinking population. Epidemiology 12, 390–395.
Carr TP, Andresen CJ & Rudel LL (1993) Enzymatic determination of triglyderide, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 26, 39–42.
Cripui MH & Ringel BL (1994) Does diet or alcohol explain the French paradox? Lancet 344, 1719–1723.
Doll R, Peto R, Hall E, Wheatley K & Gray R (1994) Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. Br Med J 309, 911–918.
Fruchart JC (2001) Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism. Am J Cardiol 88 24N – 29N
Fuchs CS, Stampfer MJ, Colditz GA, Giovannucci EL, Manson JE & Kawachi I (1995) Alcohol consumption and mortality among women. N Engl J Med 322, 1245–1250.
Gaziano JM, Gaziano TA & Glynn RJ (2000) Light-to-moderate alcohol consumption and mortality in the Physicians' Health Study. J Am Coll Cardiol 35, 96–105.
Guerre-Millo M, Gervois P, Raspé E, et al. (2000) Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275, 16638–16642.
Guo Q, Wang PR, Milot DP, Ippolito MC, Hernandez M, Burton CA, Wright SD & Chao Y (2001) Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. Biochim Biophys Acta 1533, 220–232.
Ha YC & Barter PJ (1985) Rapid separation of plasma lipoprotein by gel permeation chromatography on agarose gel Superose 6B. J Chromatogr 341, 154–159.
Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, Elis A & Aviram M (1997) Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Atherioscler Thromb Vasc Biol 17, 2744–2752.
Hoffmeister H, Schelp FP, Mensink GB, Dietz E & Bohning DR (1999) The relationship between alcohol consumption, health indicators and mortality in the German population. Int J Epidemiol 28, 1066–1072.
Honma Y, Tobe H, Makishima M, Yokoyama A & Okabe-Kado J (1998) Induction of differentiation of myelogenous leukemia cells by humulone, a bitter in the hop. Leuk Res 22, 605–610.
Kersten S, Desvergne B & Wahll W (2000) Roles of PPARs in health and disease. Nature 405, 421–424.
Mayer O, Simon J & Rosolova H (2001) A population study of the influence of beer consumption on folate and homocysteine concentrations. Eur J Clin Nutr 55, 605–609.
Mennen LI, de Courcy GP, Guilland JC, Ducros V, Zarebska M, Bertrais S, Favier A, Hercberg S & Galan P (2003) Relation between homocysteine concentrations and the consumption of different types of alcoholic beverages: the French Supplementation with Antioxidant Vitamins and Minerals Study. Am J Clin Nutr 78, 334–338.
Miranda CL, Stevens JF, Helmrich A, Henderson MC & Rodriguez RJ (1993) Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 44, 37–43.
Mizobuchi S & Sato Y (1984) A new flavanone with antifungal activity isolated from hops. Agric Biol Chem 48, 2771–2275.
Mizobuchi S & Sato Y (1985) Antifungal activity of hop bitter resins and related compounds. Agric Biol Chem 49, 399–403.
Nigdikar SV, Williams NR, Griffin BA & Howard AN (1998) Consumption of red wine polyphenols reduces the susceptibility of LDL to oxidation in vivo. Am J Clin Nutr 68, 258–265.
Nishina PM, Verstuyft J & Painen B (1990) Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res 31, 859–869.
Nishina PM, Wang J, Toyofuku W, Kuypers FA, Ishida BY & Painen B (1993) Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids 28, 599–605.
Oliver P, Plancke MO, Marzin D, Clavey V, Sauzieres J & Fruchart JC (1988) Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. Atherosclerosis 70, 107–114.
Petit D, Bonnefis MT & Infante R (1988) Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis 74, 2215–2241.
Reddy JK, Goel SK, Nemali MR, Carrino JJ, Laffler TG, Reddy MK, Sperbeck SJ, Osumi T, Hashimoto T & Lalwani ND (1986) Transcription regulation of peroxisomal fatty acyl-CoA oxidese and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proc Natl Acad Sci USA 83, 1747–1751.
Reeves PG, Nielsen FH & Fahey GC (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing on the reformation of the AIN-76 rodent diet. J Nutr 123, 1939–1951.
Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339, 1523–1526.
Schoonjans K, Staels B & Auwerx J (1996a) Role of the peroxisome proliferator-activated receptors (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37, 907–925.
Schoonjans K, Staels B & Auwerx J (1996b) The peroxisome proliferator-activated receptor (PPAR) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302, 92–109.
Sehayek E & Eisenberg S (1991) Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 270, 18259–18267.
Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K & Yamamoto S (2001) Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Biophys Res Commun 289, 220–224.
Suh I, Shaten BJ, Culter JA & Kuller LH (1992) Alcohol use and mortality from coronary artery disease: the role of high-density lipoprotein cholesterol. The Multiple Risk Factor Intervention Trial Research Group. Ann Intern Med 116, 881–887.
Tobe H, Kubota M, Yamaguchi M, Kocha T & Aoyagi T (1997a) Apoptosis to HL-60 by humulone. Biosci Biotechnol Biochem 61, 1027–1029.
Tobe H, Muraki Y, Kitamura K, Komiyama O, Sato Y, Sugioka T, Maruyama HB, Matsuda E & Nagai M (1997b) Bone resorption inhibitors from hop extract. Biosci Biotechnol Biochem 61, 158–159.
Van der Gaag MS, Ubbink JB, Sillanaukee P, Nikkari S & Hendriks HF (2000) Effect of consumption of red wine, spirits, and beer on serum homocysteine. Lancet 355, 1522.
Wang PR, Guo Q, Ippolito M, Wu M, Milot D, Ventre J, Doebber T, Wright SD & Chao YS (2001) High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor α selective agonist. Eur J Pharmacol 427, 285–293.
Yajima H, Ikeshima E, Shiraki M, Kanaya T, Fujiwara D, Odai H, Tsuboyama-Kasaoka N, Ezaki O, Oikawa S & Kondo K (2004) Isohumulones, bitter acids derived from hops, activate both peroxisome proliferators-activated receptor α and γ and reduce insulin resistance. J Biol Chem 279, 33456–33462.
Yamamoto K, Wang J, Yamamoto S & Tobe H (2000) Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid. FEBS Lett 465, 103–106.
Yasukawa K, Takeuchi M & Takido M (1995) Humulon, a bitter in the hop, inhibits tumor promotion by 12- O -tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Oncology 52, 156–158.